AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1806034 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) 250 mg as a single i.v. injection before chemotherapy
Number of subjects: 61
Study 1806034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 1806034 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP)
Number of subjects: 61
Study 6957992 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose pirenzepine therapy (100 mg/day) for 28 days
Number of subjects: 44
Study 6957992 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pirenzepine doses (50 mg/day) for 6 months
Number of subjects: 44
Study 6957992 — intervention group
Group type: COMPARATOR
Intervention: Pirenzepine withdrawal (no treatment)
Number of subjects: 44
Study 6957992 — intervention group
Group type: COMPARATOR
Intervention: Antacid therapy (28 days) followed by withdrawal
Number of subjects: 44
Study 30383298 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) + Surgical Treatment (ST)
Number of subjects: 16
Study 30383298 — intervention group
Group type: COMPARATOR
Intervention: Surgical Treatment (ST) only
Number of subjects: 16
Study 28306591 — intervention group
Group type: EXPERIMENTAL
Intervention: High PEEP group (PEEP levels of 12 cmH2O and RM)
Number of subjects: 63
Study 28306591 — intervention group
Group type: COMPARATOR
Intervention: Low PEEP group (PEEP levels of 2 cmH2O or less without RM)
Number of subjects: 63
Study 28306591 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who developed PPCs
Number of subjects: 63
Study 25480450 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally and linguistically responsive (CLR) instruction using a bilingual modality (Spanish and English)
Number of subjects: 42
Study 25480450 — intervention group
Group type: COMPARATOR
Intervention: English culturally responsive (ECR) instruction using English only
Number of subjects: 42
Study 22846413 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg 3 times daily and vitamin E 400 IU daily for 6 months
Number of subjects: 53
Study 22846413 — intervention group
Group type: COMPARATOR
Intervention: Standard follow up
Number of subjects: 53
Study 22846413 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline/vitamin E
Number of subjects: 53
Study 21701421 — intervention group
Group type: EXPERIMENTAL
Intervention: Eritoran 45 mg/105 mg
Number of subjects: 292
Study 21701421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 18081358 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.02 mg
Number of subjects: 80
Study 18081358 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.01 mg
Number of subjects: 80
Study 18081358 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.01 mg
Number of subjects: 80
Study 18081358 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 80
Study 16736338 — intervention group
Group type: EXPERIMENTAL
Intervention: TIES incision
Number of subjects: 8
Study 16736338 — intervention group
Group type: EXPERIMENTAL
Intervention: TI incision
Number of subjects: 8
Study 16736338 — intervention group
Group type: EXPERIMENTAL
Intervention: TIE incision
Number of subjects: 8
Study 16736338 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 8
Study 16736338 — intervention group
Group type: EXPERIMENTAL
Intervention: TI and TIE incisions
Number of subjects: 8
Study 16736338 — intervention group
Group type: EXPERIMENTAL
Intervention: TIE group
Number of subjects: 8
Study 16736338 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 8
Study 14665609 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2a (3 megaunits three times per week for 2 years or until recurrence)
Number of subjects: 674
Study 14665609 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (control)
Number of subjects: 674
Study 14665609 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 674
Study 11450490 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy (standard pars plana vitrectomy with creation of a posterior vitreous detachment)
Number of subjects: 21
Study 11450490 — intervention group
Group type: EXPERIMENTAL
Intervention: No preoperative macular photocoagulation
Number of subjects: 21
Study 11450490 — intervention group
Group type: COMPARATOR
Intervention: Preoperative macular laser treatment
Number of subjects: 21
Study 9395758 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 x 10(6) U of recombinant interferon-alpha-2a (IFN alpha-2a) six days a week for the first two weeks, then 6 x 10(6) U three days a week for the next 22 weeks
Number of subjects: 61
Study 9395758 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 x 10(6) U of recombinant interferon-alpha-2a (IFN alpha-2a) six days a week for the first two weeks, then 6 x 10(6) U three days a week for the next 22 weeks
Number of subjects: 61
Study 8185877 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal physostigmine
Number of subjects: 12
Study 2967625 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary NTG (200 micrograms)
Number of subjects: 26
Study 2967625 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual NIF (10 mg)
Number of subjects: 26
Study 2967625 — intervention group
Group type: COMPARATOR
Intervention: Control occlusion period
Number of subjects: 26
Study 31954959 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral-based physical therapy (CBPT-ACLR) intervention
Number of subjects: 8
Study 29908420 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg loading dose followed by 90 mg twice daily maintenance dose
Number of subjects: 3799
Study 29908420 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 300 mg loading dose followed by 75 mg/day maintenance dose
Number of subjects: 3799
Study 29908420 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 3799
Study 29908420 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 3799
Study 27866517 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic, integrated and highly‐intensive pulmonary rehabilitation for 7 days including pharmacotherapy and physical rehabilitation
Number of subjects: 48
Study 27866517 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic, integrated and highly‐intensive pulmonary rehabilitation for 7 days
Number of subjects: 48
Study 27866517 — intervention group
Group type: COMPARATOR
Intervention: Standard preoperative care
Number of subjects: 48
Study 24740371 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab high‐yield process
Number of subjects: 0
Study 24740371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23327958 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 fish oil lipid emulsion (0.2 g×kg(‐1)×d(‐1), 10%) for 14 days
Number of subjects: 53
Study 23327958 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 53
Study 20679143 — intervention group
Group type: COMPARATOR
Intervention: NVP 0 g
Number of subjects: 20
Study 20679143 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP 2.5 g
Number of subjects: 20
Study 20679143 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP 5 g
Number of subjects: 20
Study 20679143 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP 7.5 g
Number of subjects: 20
Study 18836346 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole 0.5 to 6.0 mg/d twice daily
Number of subjects: 359
Study 18836346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 359
Study 18836346 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 359
Study 16671257 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal morphine (15 microg x Kg(‐1))
Number of subjects: 59
Study 16671257 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine (0.3 mg x Kg(‐1))
Number of subjects: 59
Study 14714845 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic abutments
Number of subjects: 32
Study 14714845 — intervention group
Group type: COMPARATOR
Intervention: Titanium abutments
Number of subjects: 32
Study 10722985 — intervention group
Group type: EXPERIMENTAL
Intervention: Community activities intervention
Number of subjects: 352
Study 9196161 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium nitrate plus fluorouracil (5-FU)
Number of subjects: 34
Study 9196161 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC)
Number of subjects: 34
Study 9196161 — intervention group
Group type: COMPARATOR
Intervention: M-VAC as second-line therapy after gallium nitrate/5-FU
Number of subjects: 34
Study 9196161 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium nitrate and 5-FU
Number of subjects: 34
Study 9196161 — intervention group
Group type: COMPARATOR
Intervention: M-VAC
Number of subjects: 34
Study 1542854 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-4
Number of subjects: 73
Study 1542854 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-4 with concomitant indomethacin
Number of subjects: 73
Study 1542854 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-4 with concomitant ranitidine
Number of subjects: 73
Study 1542854 — intervention group
Group type: COMPARATOR
Intervention: Interleukin-2 and indomethacin without interleukin-4
Number of subjects: 73
Study 3539028 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol (120-160 mg/kg/day) administered by the ingastric or intravenous route
Number of subjects: 74
Study 3539028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 29448861 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-retaining barbed suture (SRBS)
Number of subjects: 60
Study 29448861 — intervention group
Group type: COMPARATOR
Intervention: Conventional absorbable polyglactin suture (non-SRBS group)
Number of subjects: 60
Study 27928815 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/daily tadalafil
Number of subjects: 183
Study 27928815 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/daily tamsulosin
Number of subjects: 183
Study 27928815 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 0.4 mg/daily tamsulosin and 20 mg/daily tadalafil
Number of subjects: 183
Study 24290078 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupportive maternal behavior at 8 months
Number of subjects: 1752
Study 24290078 — intervention group
Group type: COMPARATOR
Intervention: Overly involved maternal behavior
Number of subjects: 1752
Study 21999423 — intervention group
Group type: EXPERIMENTAL
Intervention: LESS-TEP
Number of subjects: 44
Study 21999423 — intervention group
Group type: COMPARATOR
Intervention: LAP-TEP
Number of subjects: 44
Study 19011935 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthetic mesh in a sublay position
Number of subjects: 54
Study 17334518 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ZK-807834
Number of subjects: 18
Study 17334518 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose ZK-807834
Number of subjects: 18
Study 17334518 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ZK-807834
Number of subjects: 18
Study 17334518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 16281889 — intervention group
Group type: EXPERIMENTAL
Intervention: Concept of equipoise as used by neonatologists during interviews
Number of subjects: 30
Study 16281889 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploration of equipoise at individual and community levels
Number of subjects: 30
Study 16281889 — intervention group
Group type: EXPERIMENTAL
Intervention: Balancing of benefit and harm in the context of equipoise
Number of subjects: 30
Study 11251005 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral topotecan (2.3 mg/m²/day for 5 days, every 21 days)
Number of subjects: 106
Study 11251005 — intervention group
Group type: COMPARATOR
Intervention: IV topotecan (1.5 mg/m²/day for 5 days, every 21 days)
Number of subjects: 106
Study 9556142 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous olpadronate 4 mg daily for 5 days
Number of subjects: 28
Study 9556142 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral olpadronate 200 mg daily after initial intravenous treatment
Number of subjects: 28
Study 9556142 — intervention group
Group type: COMPARATOR
Intervention: Intravenous olpadronate only (no oral maintenance)
Number of subjects: 28
Study 8291961 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback of triceps surae muscle activity during gait
Number of subjects: 0
Study 8291961 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy (PT)
Number of subjects: 0
Study 2687196 — intervention group
Group type: EXPERIMENTAL
Intervention: ioversol 320
Number of subjects: 60
Study 2687196 — intervention group
Group type: COMPARATOR
Intervention: iopamidol-300
Number of subjects: 60
Study 51964 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day cyclical combination chemotherapy
Number of subjects: 0
Study 51964 — intervention group
Group type: COMPARATOR
Intervention: 2-day cyclical combination chemotherapy
Number of subjects: 0
Study 51964 — intervention group
Group type: COMPARATOR
Intervention: 1-day cyclical combination chemotherapy
Number of subjects: 0
Study 31744314 — intervention group
Group type: EXPERIMENTAL
Intervention: MobileMums program (MMP)
Number of subjects: 0
Study 31744314 — intervention group
Group type: COMPARATOR
Intervention: Control group (minimal intervention contact)
Number of subjects: 0
Study 30595477 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (IL-6 receptor antibody) during a 12-week intervention with bicycle exercise
Number of subjects: 0
Study 30595477 — intervention group
Group type: COMPARATOR
Intervention: Placebo during a 12-week intervention with bicycle exercise
Number of subjects: 0
Study 30595477 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (IL-6 receptor antibody) with no exercise
Number of subjects: 0
Study 30595477 — intervention group
Group type: COMPARATOR
Intervention: Placebo with no exercise
Number of subjects: 0
Study 29229110 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold‐IMT (R‐IMT)
Number of subjects: 60
Study 29229110 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive‐IMT (T‐IMT)
Number of subjects: 60
Study 29229110 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 25367164 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine (ASE)
Number of subjects: 914
Study 25367164 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 914
Study 23433462 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal tube
Number of subjects: 40
Study 23433462 — intervention group
Group type: EXPERIMENTAL
Intervention: Combitube
Number of subjects: 40
Study 23433462 — intervention group
Group type: EXPERIMENTAL
Intervention: EasyTube
Number of subjects: 40
Study 23433462 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 40
Study 23433462 — intervention group
Group type: EXPERIMENTAL
Intervention: I-Gel
Number of subjects: 40
Study 23433462 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal intubation
Number of subjects: 40
Study 20945064 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine alone for 10 weeks
Number of subjects: 307
Study 20945064 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine combined with behavioral training for 10 weeks
Number of subjects: 307
Study 19767148 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional diagnosis presented by a physician with a biomedical orientation
Number of subjects: 160
Study 19767148 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional diagnosis presented by a physician with a biopsychosocial orientation
Number of subjects: 160
Study 19767148 — intervention group
Group type: COMPARATOR
Intervention: Organic diagnosis
Number of subjects: 160
Study 22291076 — intervention group
Group type: EXPERIMENTAL
Intervention: Single high-dose chemotherapy (VIP + 3 cycles of high-dose carboplatin and etoposide)
Number of subjects: 211
Study 22291076 — intervention group
Group type: COMPARATOR
Intervention: Sequential high-dose chemotherapy (3 cycles of VIP + 1 cycle of high-dose carboplatin, etoposide, and cyclophosphamide)
Number of subjects: 211
Study 15034720 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental drainage method
Number of subjects: 958
Study 15034720 — intervention group
Group type: COMPARATOR
Intervention: Controlled cord traction method
Number of subjects: 958
Study 12187294 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cholesterol content formula (< 0.03 g/L)
Number of subjects: 30
Study 12187294 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium cholesterol content formula (0.15 g/L)
Number of subjects: 30
Study 12187294 — intervention group
Group type: EXPERIMENTAL
Intervention: High cholesterol content formula (0.30 g/L)
Number of subjects: 30
Study 12187294 — intervention group
Group type: COMPARATOR
Intervention: All groups (low, medium, high cholesterol)
Number of subjects: 30
Study 9856918 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 2 mg for 5 weeks
Number of subjects: 16
Study 9856918 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg for 10 weeks
Number of subjects: 16
Study 9856918 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg/day
Number of subjects: 16
Study 9856918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9856918 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin and Placebo
Number of subjects: 16
Study 7825521 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron supplementation (30 mg Fe daily for 8 weeks)
Number of subjects: 87
Study 7825521 — intervention group
Group type: COMPARATOR
Intervention: Twice weekly iron supplementation (30 mg Fe twice per week for 8 weeks)
Number of subjects: 87
Study 2214868 — intervention group
Group type: EXPERIMENTAL
Intervention: IMREG‐1 (immunosupportive biological agent derived from human leukocytes)
Number of subjects: 0
Study 2214868 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 89449 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 73
Study 89449 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP)
Number of subjects: 73
Study 89449 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytology
Number of subjects: 73
Study 89449 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised tomography, angiography, and scintigraphy
Number of subjects: 73
Study 89449 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ERCP and direct ductal aspiration for cytology
Number of subjects: 73
Study 31325257 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin (5 mg/day)
Number of subjects: 20
Study 31325257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 27004945 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 41
Study 27004945 — intervention group
Group type: COMPARATOR
Intervention: Miller laryngoscope
Number of subjects: 41
Study 25552367 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined EpCAM/MCAM CellSearch enrichment
Number of subjects: 68
Study 25552367 — intervention group
Group type: COMPARATOR
Intervention: MCAM-positive CTCs
Number of subjects: 68
Study 25552367 — intervention group
Group type: EXPERIMENTAL
Intervention: EpCAM-positive CTCs and CEC counts
Number of subjects: 68
Study 23509093 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week smoking cessation intervention
Number of subjects: 49
Study 23509093 — intervention group
Group type: EXPERIMENTAL
Intervention: Prequit affective trajectories
Number of subjects: 49
Study 23509093 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of prequit affective trajectory and abstinence
Number of subjects: 49
Study 19756024 — intervention group
Group type: EXPERIMENTAL
Intervention: German honey varieties (5 of 8 tested)
Number of subjects: 10
Study 19756024 — intervention group
Group type: EXPERIMENTAL
Intervention: German honey varieties (6 of 8 tested)
Number of subjects: 10
Study 19756024 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycaemic index and insulinaemic index
Number of subjects: 10
Study 19756024 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific honey varieties
Number of subjects: 10
Study 18086067 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq
Number of subjects: 79
Study 18086067 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 79
Study 16877901 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg/day)
Number of subjects: 483
Study 16877901 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 483
Study 16877901 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine XR
Number of subjects: 483
Study 14520141 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 63
Study 14520141 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 63
Study 10890289 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite smoking cessation program
Number of subjects: 844
Study 8888657 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 15
Study 8888657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1900483 — intervention group
Group type: COMPARATOR
Intervention: hMG (group A)
Number of subjects: 302
Study 1900483 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist followed by hMG stimulation (group B)
Number of subjects: 302
Study 6618393 — intervention group
Group type: COMPARATOR
Intervention: Sportgel treatment
Number of subjects: 197
Study 30224319 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 500 μg once daily for 16 weeks
Number of subjects: 158
Study 30224319 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 16 weeks
Number of subjects: 158
Study 27093068 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 0
Study 27093068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25243084 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions intervention
Number of subjects: 98